LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

@article{RorickKehn2014LY2456302IA,
  title={LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders},
  author={Linda M. Rorick-Kehn and Jeffrey M. Witkin and Michael A. Statnick and Elizabeth Lutz Eberle and Jamie H. McKinzie and Steven D. Kahl and Beth M. Forster and C. K. Lin B. K. L. So J. N. S. Leung H. K. Wong and Xia Li and Robert S Crile and David B Shaw and Allison E. Sahr and Benjamin L. Adams and Steven Quimby and Nuria D{\'i}az and Alma Guadalupe Rojo Jimenez and Concepci{\'o}n Pedregal and Charles Mitch and Kelly L. Knopp and Wesley H. Anderson and Jeffrey W. Cramer and David L Mckinzie},
  journal={Neuropharmacology},
  year={2014},
  volume={77},
  pages={131-144}
}
Kappa opioid receptors and their endogenous neuropeptide ligand, dynorphin A, are densely localized in limbic and cortical areas comprising the brain reward system, and appear to play a key role in modulating stress and mood. Growing literature indicates that kappa receptor antagonists may be beneficial in the treatment of mood and addictive disorders. However, existing literature on kappa receptor antagonists has used extensively JDTic and nor-BNI which exhibit long-lasting pharmacokinetic… CONTINUE READING
Highly Cited
This paper has 30 citations. REVIEW CITATIONS
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 59 references

Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats.

The Journal of pharmacology and experimental therapeutics • 2003
View 5 Excerpts
Highly Influenced

Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses.

The Journal of neuroscience : the official journal of the Society for Neuroscience • 2003
View 4 Excerpts
Highly Influenced

Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway.

Proceedings of the National Academy of Sciences of the United States of America • 1992
View 4 Excerpts
Highly Influenced

Opioid receptor blocker shows promise in phase II depression trial

C. Harrison
Nat. Rev. Drug Discov • 2013
View 1 Excerpt

A pilot study of ALKS 5461 (Buprenorphine combined with ALKS 33) in treatment resistant depression

M. Fava, J. A. Bodkin, +5 authors E. Ehrich
NCDEU Conference Abstract, • 2012
View 1 Excerpt